1063407-94-2

Upstream product

• 1063407-93-1 N,N-dimethyl-2-(7-nitro-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)ethanamine 
• 1885-14-9 phenyl chloroformate 
• 1063407-23-7 1-(2-(dimethylamino)ethyl)-7-nitro-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one 
• 22246-45-3 1,3,4,5-Tetrahydro-7-nitro-2H-benzazepin-2-on 

Downstream Products

• 1063407-96-4 phenyl 2-(7-amino-2,3,4,5-tetrahydro-11H-benzo[b]azepin-1-yl)ethyl(methyl)carbamate 
• 1063407-97-5 phenyl-methyl(2-(7-(thiophene-2-carboximidamido)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)ethyl)carbamate 

Relevant academic research and scientific papers

Novel, druglike 1,7-disubstituted 2,3,4,5-tetrahydro-1H-benzo[b]azepine- based selective inhibitors of human neuronal nitric oxide synthase (nNOS)

A novel class of 1,7-disubstituted 2,3,4,5-tetrahydro-1H-benzo[b]azepine derivatives was designed, synthesized and evaluated as human nitric oxide synthase (NOS) inhibitors. Structure-activity relationship studies based on various basic amine side chains

QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY

The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.